Impact lands runway to clear multiple synthetic lethality milestones

A $61 million financing will give Impact runway until YE23 by which time the Shanghai synthetic lethality company hopes to have its first NDA to NMPA and a strategic partnership in place for its WEE1 inhibitor. 

Impact Therapeutics Inc.’s more immediate inflection points, CEO Jun Bao told BioCentury, include data for multiple programs at this year’s American Society of Clinical Oncology meeting...